Nuvama reaffirms Buy on Vedanta. 3 reasons why…

The brokerage firm Nuvama has reaffirmed its ‘Buy’ on Vedanta, maintaining a target price of Rs 663 based on FY27E sum-of-the-parts valuation. According to brokerage firm, the growth prospects for Vedanta remain intact, defined by it positive performance across multiple segments.

3 reasons why the firm continues to rate the stock as a ‘Buy’ – 1. Strong earnings performance in Q3

The brokerage firm highlighted that “higher aluminium prices offset the greater alumina cost,” which helped the company improve the aluminium EBITDA per tonne in Q3.

Furthermore, the aluminium segment, which plays a crucial role in the overall profitability, saw increased earnings despite rising costs. Alongside gains in zinc, iron ore, and oil business, consolidated EBITDA rose 13% quarter-on-quarter to Rs 111 billion surpassing the brokerage estimate at Rs 104.7 billion.

Also ReadMarkets close lower: Nifty below 23,400, Sensex slides over 300 points; L&T, Tata Motors among losers 2. Aluminium and Zinc to drive EBITDA growth with lower costs and stable prices

Looking forward, the brokerage firm is optimistic about the near-term results. The brokerage house expects “a 10%+ QoQ jump in Q4 EBITDA amid firm prices and lower CoP in aluminium and zinc.”

This anticipated improvement comes as the cost benefits begin to materialise, particularly in the aluminium segment where lower alumina prices are expected to show up predominantly in Q1FY26.

3. Value unlock through demerger

Another key reason for the brokerage continued buy rating is the potential demerger of Vedanta’s business. The firm notes that the demerger is “likely to be concluded by end-Q1FY26” once approvals are secured from lenders and equity shareholders (expected by 18th Feb-25).

According to the brokerage firm, this move is expected to unlock additional value by streamlining operations and enhancing focus on core segments positioning the company in the first decile of the global cost curve by FY28E.

Also ReadHUDCO shares fall 12% as Budget disappoints on policy boost and capex Vedanta Q3FY25 performance

Vedanta in Q3 FY25 reported 76.2% rise in net profit, reaching Rs 3,547 crore, up from Rs 2,013 crore in Q3 FY24. The company also saw a 10% increase in revenue, totalling Rs 38,526 crore compared to Rs 34,968 crore last year. In addition to it, Vedanta achieved its highest-ever Q3 EBITDA of Rs 11,284 crore,

 » Read More

Related Articles

8th Pay Commission: Central govt to merge pay scales for Level 1-6 employees? Here’s what the new proposal says

8th Pay Commission: The National Council of Joint Consultative Machinery (JCM) Staff Side has submitted its recommendations for the Terms of Reference (ToR) for the 8th Central Pay Commission (CPC), advocating significant changes in pay structure, allowances and benefits for government employees. Among the key points of ToR is the proposal for merger of certain

Bharti Airtel Q3 Results: Profit surges 505.24% to Rs 14,781.20 crore, ARPU at Rs 245

Bharti Airtel on Thursday posted a profit of Rs 14,781.20 crore during the third quarter of FY25, reporting a growth of 505.24 per cent in comparison to Rs 2442.20 crore during the corresponding quarter of FY24. The telecom major recorded Q3 revenue from operations at Rs 45,129.30 crore, up 19.08 per cent as against Rs

JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…

Jefferies has maintained a Buy on JB Pharma with a revised target price of Rs 2,310. The stock currently trades at Rs 1,714/share implying an 34% upside. This new target price is just a shade lower than the previous target price of Rs 2,340. According to Jefferies, an international brokerage house, the growth drivers are

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

8th Pay Commission: Central govt to merge pay scales for Level 1-6 employees? Here’s what the new proposal says

8th Pay Commission: The National Council of Joint Consultative Machinery (JCM) Staff Side has submitted its recommendations for the Terms of Reference (ToR) for the 8th Central Pay Commission (CPC), advocating significant changes in pay structure, allowances and benefits for government employees. Among the key points of ToR is the proposal for merger of certain

Bharti Airtel Q3 Results: Profit surges 505.24% to Rs 14,781.20 crore, ARPU at Rs 245

Bharti Airtel on Thursday posted a profit of Rs 14,781.20 crore during the third quarter of FY25, reporting a growth of 505.24 per cent in comparison to Rs 2442.20 crore during the corresponding quarter of FY24. The telecom major recorded Q3 revenue from operations at Rs 45,129.30 crore, up 19.08 per cent as against Rs

JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…

Jefferies has maintained a Buy on JB Pharma with a revised target price of Rs 2,310. The stock currently trades at Rs 1,714/share implying an 34% upside. This new target price is just a shade lower than the previous target price of Rs 2,340. According to Jefferies, an international brokerage house, the growth drivers are

Two banking stocks to watch ahead of the RBI Policy

By Kiran Jani Bank Nifty reached its all-time high of 54,467 in September 2024. Following this peak, the index experienced a correction, dipping to 47,844 in January 2025—a decline of 7.29%. Despite this pullback, Kotak Bank and ICICI Bank showed relative resilience, delivering returns of 1.61% and -4.20%, respectively, during the same period. Source: Investing.com

New Tax Regime: These deductions, exemptions still available for you

The Indian government introduced a new tax regime in 2020, offering lower tax rates while removing several exemptions and deductions available under the old system. Initially optional, this regime became the default in 2023, requiring taxpayers to opt out if they wished to continue under the old structure. Despite the removal of many benefits, certain